Navigation Links
AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
Date:2/12/2008

d additional information are available at http://www.aeternazentaris.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
2. AEterna Zentaris Announces Outcome of Managements Strategic Review
3. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
4. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
5. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
6. Immtech Reports Fiscal Third Quarter 2008 Results
7. Phlo Affiliate Reports Progress in New York City Metropolitan Area Roll-Out
8. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
9. Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007
10. Bunge Reports Fourth Quarter Net Income of $245 Million
11. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ... today reported financial results for the six months ... are expressed in Canadian dollars and presented under ... Quarter 2014 Highlights , Announced top-line ... (VA) primary endpoint for subjects enrolled in the ...
(Date:8/29/2014)... 2014 Three Lawrence Livermore researchers ... Hydrogen Production R&D Award for their research ... using sunlight. , Shared with collaborators from the ... of Nevada, Las Vegas (UNLV), the award recognizes ... photoelectrochemical solar-hydrogen production and corrosion processes. , These ...
(Date:8/29/2014)... 2014 A major challenge before new ... dense realm of Boston-Cambridge, is gaining visibility that can ... Sherley, the Director of Boston’s Adult Stem Cell Technology ... national visibility of his company an important priority since ... addition to a social media marketing campaign ...
(Date:8/28/2014)... SAN DIEGO, California, USA (PRWEB) August 28, 2014 ... at the Department of Physics and Optical Science and ... at the University of North Carolina at Charlotte, and ... has been elected to serve as the 2015 Vice ... photonics. , SPIE 2014 President Philip Stahl announced recent ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Livermore Team Awarded for Hydrogen Production Research 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2
... Veteran healthcare executive brings solid experience with international ... healthcare and technology companies, ... management tools, announced the appointment of,Guillermo Moreno as its vice ... for developing and implementing strategic,initiatives to grow the company,s business ...
... Corporation,(Nasdaq: SIAL ) will be presenting at the ... at 8:30 AM ET at the Grand Hyatt in,New ... broadcast over the,Internet available at http://ir.sigmaaldrich.com . Users ... the webcast on, http://ir.sigmaaldrich.com users will need to ...
... FREMONT, Calif., Sept. 17 Quark ... and developing novel,RNA interference (RNAi)-based therapeutics, ... the 5th Annual RNAi Europe, taking ... Three of Quark,s scientists,Igor Mett, Hagar ...
Cached Biology Technology:Guillermo Moreno Named Aurillion's Vice President of Sales and Marketing 2Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008 2Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008 3
(Date:8/28/2014)... Clinic researcher and his collaborators have developed an online ... process of re-engineering cells for biomedical investigation. CellNet is ... to aid stem cell engineering. Details of CellNet and ... two back-to-back papers in the journal Cell . ... uses for all types of cell-based investigations and can ...
(Date:8/28/2014)... MD FASEB MARC (Maximizing Access to Research ... for the Genetics Society of America,s 27th Annual ... October 3, 2014 in Pacific Grove, California. ... of students, post doctorates and scientists from underrepresented ... community and to encourage the participation of young ...
(Date:8/28/2014)... -- Scientists have identified the developmental on-off switch for ... produce more than two-thirds of the world,s naturally derived ... to see whether it is possible to manipulate this ... , The study, appearing August 28 in Cell ... molecule called cyclic-di-GMP and a larger protein called BldD ...
Breaking Biology News(10 mins):New tool aids stem cell engineering for medical research 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... The World Science Festival launches its first full day with ... will feature a keynote address by Harold Varmus, co-chair of ... well as a live simulcast of the announcement of the ... Oslo, Norway. A panel discussion follows, moderated by Elizabeth ...
... (May 14, 2010)--The New York Stem Cell Foundation (NYSCF) ... Robertson Foundation, established by Julian and Josie Robertson. ... will provide funding for NYSCF-Robertson Investigators in NYSCF,s new ... the NYSCF-Robertson Stem Cell Prize. This award ...
... 2010 The same digital technology that enables young people ... immerse them in a simulated coral reef environment where they ... project led by Field Museum scientists will link students from ... reef environments in the Pacific Ocean, engage in the scientific ...
Cached Biology News:Field Museum technology project wins prestigious award 2
... Isothermal Block is an anodized aluminum, solvent-resistant ... and to provide efficient thermal transfer to ... design of the HT96 Isothermal Block replaces ... product design allowing for compatibility with robotic ...
Human monocyte-derived dendritic cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
...
...
Biology Products: